paclitaxel has been researched along with Hematuria in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ichikawa, K; Kuwada, M; Maruyama, Y; Otani, T; Sakamoto, K; Yoshikawa, T | 1 |
| Chen, L; Dong, C; He, X; Liu, Y; Shu, Y; Wu, P | 1 |
| Ichimaru, N; Kojima, Y; Nonomura, N; Okumi, M; Takahara, S; Takahi, Y | 1 |
| Dewan, P; Lin, DW; Montgomery, RB; Wright, JL | 1 |
| Barnes, CS; Cowan, KH; Denicoff, AM; Goldspiel, BR; Gossard, MR; Kohler, DR; McCabe, M; Noone, MH; O'Shaughnessy, JA; Tolcher, AW; Zujewski, J | 1 |
| Eisenhauer, E; Latreille, J; Paul, K; Shepherd, FA | 1 |
2 trial(s) available for paclitaxel and Hematuria
| Article | Year |
|---|---|
Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Equipment Failure; Erythrocyte Transfusion; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Home Infusion Therapy; Humans; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1996 |
Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carcinoma, Non-Small-Cell Lung; Confusion; Dexamethasone; Diphenhydramine; Drug Tolerance; Female; Hematuria; Humans; Ifosfamide; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Muscular Diseases; Neutropenia; Paclitaxel; Paresthesia; Survival Rate; Treatment Outcome | 1996 |
4 other study(ies) available for paclitaxel and Hematuria
| Article | Year |
|---|---|
[A Case of Refractory Intermittent Hematuria that Occurred during Paclitaxel/Ramucirumab Combination Therapy for Metastatic Gastric Cancer].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Hematuria; Humans; Male; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2022 |
Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Endothelial Cells; Female; Hematuria; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Programmed Cell Death 1 Receptor; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A | 2023 |
Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Hematuria; Humans; Kidney Transplantation; Lung Neoplasms; Male; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Bone Marrow Neoplasms; Bone Neoplasms; Hematuria; Humans; Hydronephrosis; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Renal Dialysis; Renal Insufficiency; Tumor Lysis Syndrome | 2005 |